Abstract
The p53 protein plays a central role in regulating apoptosis. The loss of functional p53 is common in many cancers. In cancer cells, the dysfunctional p53 protein often maintains a misfolded, inactive conformation due to genetic mutations or posttranslational deregulation. The misfolded p53 protein can aggregate and form amyloid-like oligomers and fibrils, which abrogate the pro-apoptotic functions of p53. Therefore, the aggregation of p53 may be a crucial factor in carcinogenesis, tumor progression, and the response of cancer cells to apoptotic signals. In this chapter, we provide details on various methods for detecting p53 aggregation in cancer cell lines and tumor samples.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zilfou JT, Lowe SW (2009) Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 1(5):a001883. doi:10.1101/cshperspect.a001883
Michael D, Oren M (2002) The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 12(1):53–59, S0959437X01002647 [pii]
Chen J, Ng SM, Chang C, Zhang Z, Bourdon JC, Lane DP, Peng J (2009) p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev 23(3):278–290. doi:10.1101/gad.1761609, 23/3/278 [pii]
Chan WM, Poon RY (2007) The p53 isoform Deltap53 lacks intrinsic transcriptional activity and reveals the critical role of nuclear import in dominant-negative activity. Cancer Res 67(5):1959–1969. doi:10.1158/0008-5472.CAN-06-3602, 67/5/1959 [pii]
Stefani M, Dobson CM (2003) Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med (Berl) 81(11):678–699. doi:10.1007/s00109-003-0464-5
Silva JL, Rangel LP, Costa DC, Cordeiro Y, De Moura Gallo CV (2013) Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor. Biosci Rep 33(4):e00054. doi:10.1042/BSR20130065, BSR20130065 [pii]
Aguzzi A, O’Connor T (2010) Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 9(3):237–248. doi:10.1038/nrd3050, nrd3050 [pii]
Rigacci S, Bucciantini M, Relini A, Pesce A, Gliozzi A, Berti A, Stefani M (2008) The (1–63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies. Biophys J 94(9):3635–3646. doi:10.1529/biophysj.107.122283, S0006-3495(08)70440-5 [pii]
Ishimaru D, Andrade LR, Teixeira LS, Quesado PA, Maiolino LM, Lopez PM, Cordeiro Y, Costa LT, Heckl WM, Weissmuller G, Foguel D, Silva JL (2003) Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry 42(30):9022–9027. doi:10.1021/bi034218k
Higashimoto Y, Asanomi Y, Takakusagi S, Lewis MS, Uosaki K, Durell SR, Anderson CW, Appella E, Sakaguchi K (2006) Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer. Biochemistry 45(6):1608–1619. doi:10.1021/bi051192j
Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S, Cornelis A, Rozenski J, Zwolinska A, Marine JC, Lambrechts D, Suh YA, Rousseau F, Schymkowitz J (2011) Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 7(5):285–295. doi:10.1038/nchembio.546, nchembio.546 [pii]
Khurana R, Coleman C, Ionescu-Zanetti C, Carter SA, Krishna V, Grover RK, Roy R, Singh S (2005) Mechanism of thioflavin T binding to amyloid fibrils. J Struct Biol 151(3):229–238. doi:10.1016/j.jsb.2005.06.006, S1047-8477(05)00130-9 [pii]
Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2:18. doi:10.1186/1750-1326-2-18, 1750-1326-2-18 [pii]
Vassar PS, Culling CF (1959) Fluorescent stains, with special reference to amyloid and connective tissues. Arch Pathol 68:487–498
Brancroft J, Gamlble M (2002) Theory and practice of histological techniques, 5th edn. Churchill Livingstone, London
Linke R (2006) Congo red staining of amyloid: improvements and practical guide for a more precise diagnosis of amyloid and the different amyloidoses. In: Uversky VN, Fink AL (eds) Protein misfolding, aggregation, and conformational diseases, vol 4. Springer, New York, pp 239–376
Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13(1):45–53, 0896-6273(94)90458-8 [pii]
Fukumoto H, Asami-Odaka A, Suzuki N, Iwatsubo T (1996) Association of A beta 40-positive senile plaques with microglial cells in the brains of patients with Alzheimer’s disease and in non-demented aged individuals. Neurodegeneration 5(1):13–17
Hrncic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT, Solomon A (2000) Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 157(4):1239–1246. doi:10.1016/S0002-9440(10)64639-1, S0002-9440(10)64639-1 [pii]
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Yang-Hartwich, Y., Bingham, J., Garofalo, F., Alvero, A.B., Mor, G. (2015). Detection of p53 Protein Aggregation in Cancer Cell Lines and Tumor Samples. In: Mor, G., Alvero, A. (eds) Apoptosis and Cancer. Methods in Molecular Biology, vol 1219. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1661-0_7
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1661-0_7
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-1660-3
Online ISBN: 978-1-4939-1661-0
eBook Packages: Springer Protocols